shangrilabio
RK Anticancer agent
- HOME
- BUSINESS
- RK Anticancer agent
Anticancer drug through a new mechanism
Anticancer drug through a new mechanism
- The research team of Dr. Masaru Taniguchi of the Japan Institute of Physical and Chemical Research (RIKEN) synthesized a derivative of a ligand essential for an anti-tumor immune response to NKT cells.
- A new ligand obtained through screening for NKT cell activation ability and anti-tumor effect
- Development of a new anticancer drug that induces the activation of anticancer immune cells through simultaneous clinical trials in Japan and Korea in collaboration with the headquarters of Shangrila Bio, Japan
Core technology and development content
- Induce immune cell activity with simpler injectable anticancer drugs to simplify the process of anti-cancer immune cell therapy that activates immune cells
- In non-clinical experiments, the effect of inhibiting cancer formation was remarkably excellent and the side effects were small
- Commercialization of RK anticancer drugs through non-clinical/clinical testing
